3696 — Insilico Medicine Cayman TopCo Balance Sheet
0.000.00%
Last trade - 00:00- HK$42.01bn
- HK$40.41bn
- $85.83m
Annual balance sheet for Insilico Medicine Cayman TopCo, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|
| Period Length: | — | — | — |
| Source: | PROSPECTUS | PROSPECTUS | PROSPECTUS |
| Standards: | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final |
| Cash | |||
| Short Term Investments | |||
| Cash and Short Term Investments | 208 | 177 | 126 |
| Net Total Accounts Receivable | |||
| Net Total Receivables | 6.32 | 4.91 | 4.69 |
| Prepaid Expenses | |||
| Total Other Current Assets | |||
| Total Current Assets | 219 | 189 | 133 |
| Gross Property, Plant And Equipment | |||
| Accumulated Depreciation | |||
| Net Property, Plant And Equipment | 14.3 | 12.8 | 9.44 |
| Net Intangible Assets | |||
| Long Term Investments | |||
| Other Long Term Assets | |||
| Total Assets | 235 | 203 | 144 |
| Accounts Payable | |||
| Accrued Expenses | |||
| Notes Payable / Short Term Debt | |||
| Current Portion of Long Term Debt / Capital Leases | |||
| Total Other Current Liabilities | |||
| Total Current Liabilities | 682 | 852 | 807 |
| Capital Lease Obligations | |||
| Total Long Term Debt | |||
| Total Debt | |||
| Total Liabilities | 684 | 853 | 808 |
| Common Stock | |||
| Additional Paid In Capital | |||
| Retained Earnings (Accumulated Deficit) | |||
| Treasury Stock | |||
| Other Equity | |||
| Total Equity | -450 | -650 | -664 |
| Total Liabilities & Shareholders' Equity | 235 | 203 | 144 |
| Total Common Shares Outstanding |